🔎 Trials Near Me

Utama › Kanser Payudara › Michigan › Detroit

Kajian klinikal Kanser Payudara di Detroit, MI

33 kajian untuk Kanser Payudara sedang mencari peserta di lokasi dalam dan sekitar Detroit (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

The Vanguard Study: Testing a New Way to Screen for Cancer

Mengambil pesertaSukarelawan sihat dialu-alukan
  • Henry Ford Hospital, Detroit
  • Henry Ford Medical Center - Detroit Northwest, Detroit
Umur 45 hingga 75 · Semua jantina · Dikemas kini 5 Okt 2026 · NCT06995898

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • Henry Ford Hospital, Detroit
  • Henry Ford Health Saint John Hospital, Detroit
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Mengambil pesertaFasa 2
  • Henry Ford Hospital, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07102381

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Mengambil peserta
  • Karmanos Cancer Center - Wayne State University, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07214532

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Mengambil pesertaFasa 1
  • Barbara Ann Karmanos Cancer Institute, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Mengambil pesertaFasa 1
  • Barbara Ann Karmanos Cancer Institute, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07213791

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Mengambil pesertaFasa 1/2
  • Karmanos Cancer Institute, Detroit
  • Brigitte Harris Cancer Pavilion BHCP, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06827236

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Mengambil pesertaFasa 3
  • Karmanos Cancer Center, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07173751

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Mengambil pesertaFasa 1
  • Karmanos Cancer Institiute, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Mengambil pesertaFasa 1
  • Henry Ford Cancer Institute, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06253871

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Mengambil pesertaFasa 1/2
  • Henry Ford Hospital, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT05386108

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • Wayne State University - Barbara Ann Karmanos Cancer Institute, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07287917

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Mengambil pesertaFasa 3
  • Wayne State University/Karmanos Cancer Institute, Detroit
  • Henry Ford Hospital, Detroit
  • Henry Ford Health Saint John Hospital, Detroit
Umur 18 hingga 60 · Wanita · Dikemas kini 2 Sep 2026 · NCT05879926

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

Mengambil peserta
  • Karmanos Cancer Institute, Detroit
Umur 22 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT07227831

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Mengambil pesertaFasa 3
  • Wayne State University/Karmanos Cancer Institute, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06500481

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Mengambil pesertaFasa 2/3
  • Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT06926868

E-Mindfulness Approaches for Living After Breast Cancer

Mengambil pesertaFasa 3
  • Henry Ford Hospital, Detroit
Umur 18 hingga 50 · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT06748222

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Mengambil pesertaFasa 1/2
  • Karmanos Cancer Institute, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT05579366

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

Mengambil pesertaSukarelawan sihat dialu-alukan
  • Henry Ford Health, Detroit
Umur 45 hingga 74 · Wanita · Dikemas kini 31 Jul 2026 · NCT05625659

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Mengambil pesertaFasa 1/2
  • Henry Ford Health Hospital, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT05377996

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Mengambil pesertaFasa 1/2
  • Henry Ford Hospital, Detroit
Umur 18 ke atas · Wanita · Dikemas kini 22 Jun 2026 · NCT05573126

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Mengambil pesertaFasa 3
  • Henry Ford Health System, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mei 2026 · NCT06757634

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Mengambil pesertaFasa 3
  • Wayne State University/Karmanos Cancer Institute, Detroit
  • Henry Ford Hospital, Detroit
  • Henry Ford Health Saint John Hospital, Detroit
Umur 50 hingga 70 · Semua jantina · Dikemas kini 23 Apr 2026 · NCT04852887

A Study of the TheraBionic P1 Device in Breast Cancer

Mengambil peserta
  • Karmanos Cancer Institute, Detroit
Umur 22 ke atas · Wanita · Dikemas kini 21 Apr 2026 · NCT07218432

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Mengambil pesertaFasa 1/2
  • Henry Ford Health System, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Apr 2026 · NCT05785741

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Mengambil pesertaFasa 1/2
  • Karmanos Cancer Institute, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Apr 2026 · NCT05735080

F-Tryptophan PET/CT in Human Cancers

Mengambil pesertaFasa 1
  • Karmanos Cancer Institute, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jan 2026 · NCT05556473

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Mengambil pesertaFasa 3
  • Wayne State University/Karmanos Cancer Institute, Detroit
  • Henry Ford Hospital, Detroit
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Okt 2025 · NCT03418961

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

Mengambil peserta
  • Karmanos Cancer Institute, Detroit
Umur 18 ke atas · Wanita · Dikemas kini 18 Sep 2025 · NCT07095114

Kajian Kanser Payudara di bandar lain

Kajian lain di Detroit

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.